Open Access Articles- Top Results for Nicardipine


Systematic (IUPAC) name
2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Clinical data
Trade names Cardene
AHFS/ monograph
MedlinePlus a695032
  • (Prescription only)
Oral, intravenous
Pharmacokinetic data
Protein binding >95%
Half-life 8.6 hours
55985-32-5 7pxY
PubChem CID 4474
IUPHAR ligand 2559
DrugBank DB00622 7pxY
ChemSpider 4319 7pxY
UNII CZ5312222S 7pxY
KEGG D08270 7pxY
Chemical data
Formula C26H29N3O6
479.525 g/mol
Physical data
Melting point Script error: No such module "convert".
 14pxY (what is this?)  (verify)

Nicardipine hydrochloride (Cardene) is a medication used to treat high blood pressure and angina. It belongs to the class of calcium channel blockers.

Nicardipine is a dihydropyridine calcium-channel blocking agent used for the treatment of vascular disorders such as chronic stable angina, hypertension, and Raynaud's phenomenon. It is available in oral and intravenous formulations. Its mechanism of action and clinical effects closely resemble those of nifedipine and the other dihydropyridines (amlodipine, felodipine), except that nicardipine is more selective for cerebral and coronary blood vessels. Furthermore, nicardipine does not intrinsically decrease myocardial contractility and may be useful in the management of congestive heart failure. Nicardipine also has a longer half-life than nifedipine. Nicardipine was approved by the FDA in December 1988. The patent for both Cardene and Cardene SR expired in October 1995.[1]

It has been used in percutaneous coronary intervention.[2]


  1. ^ Nicardipine at Medline PLus
  2. ^ Huang RI, Patel P, Walinsky P et al. (November 2006). "Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention". Catheter Cardiovasc Interv 68 (5): 671–6. PMID 17034064. doi:10.1002/ccd.20885.